Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors

Hypertension

Volumn 67, Issue 2, 2016, Pages 368-377

  Moody, William E ^a   Ferro, Charles J ^b   Edwards, Nicola C ^a   Chue, Colin D ^a   Lin, Erica Lai Sze ^a   Taylor, Robin J ^a   Cockwell, Paul ^b   Steeds, Richard P ^a   Townend, Jonathan N ^a  

^a Birmingham Cardio Renal Group   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Blood pressure; glomerular filtration rate; heart ventricles; left ventricular remodeling; vascular stiffness

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; TROPONIN T; URIC ACID;

ADULT; AGED; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MONITORING; BRAIN ISCHEMIA; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HUMAN TISSUE; KIDNEY DONOR; KIDNEY FUNCTION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; UNINEPHRECTOMY; URIC ACID BLOOD LEVEL; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; FOLLOW UP; INCIDENCE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MIDDLE AGED; NEPHRECTOMY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE BLIND PROCEDURE; UNITED KINGDOM;

ADULT; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; NEPHRECTOMY; PROSPECTIVE STUDIES; RISK FACTORS; SINGLE-BLIND METHOD; UNITED KINGDOM;

EID: 84956857936     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.06608     Document Type: Article

References (51)

1. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet. 2010;375:2073-2081.
2. Mafham M, Emberson J, Landray MJ, Wen CP, Baigent C. Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis. PLoS One. 2011;6:e25920. doi: 10.1371/journal. pone.0025920.
3. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260-272. doi: 10.1016/S0140-6736(13)60687-X.
4. Coresh J, Longenecker JC, Miller ER III, Young HJ, Klag MJ. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol. 1998;9(12 suppl):S24-S30.
5. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63:793-808. doi: 10.1046/j.1523-1755.2003.00803.x.
6. United States Renal Data System. 2015 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD: USRDS; 2015.
7. Mark PB, Johnston N, Groenning BA, Foster JE, Blyth KG, Martin TN, Steedman T, Dargie HJ, Jardine AG. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int. 2006;69:1839-1845. doi: 10.1038/sj.ki.5000249.
8. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999;99:2434-2439.
9. Krohn AG, Ogden DA, Holmes JH. Renal function in 29 healthy adults before and after nephrectomy. JAMA. 1966;196:322-324.
10. Ibrahim HN, Rogers T, Tello A, Matas A. The performance of three serum creatinine-based formulas in estimating GFR in former kidney donors. Am J Transplant. 2006;6:1479-1485. doi: 10.1111/j.1600-6143.2006.01335.x.
11. Barri YM, Parker T III, Daoud Y, Glassock RJ. Definition of chronic kidney disease after uninephrectomy in living donors: what are the implications Transplantation. 2010;90:575-580. doi: 10.1097/TP.0b013e3181e64237.
12. Moody WE, Tomlinson LA, Ferro CJ, Steeds RP, Mark PB, Zehnder D, Tomson CR, Cockcroft JR, Wilkinson IB, Townend JN. Effect of A Reduction in glomerular filtration rate after NEphrectomy on arterial STiffness and central hemodynamics: rationale and design of the EARNEST study. Am Heart J. 2014;167:141-149.e2. doi: 10.1016/j. ahj.2013.10.024.
13. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology. 2007;18:800-804. doi: 10.1097/EDE.0b013e3181577654.
14. British Transplantation Society/The Renal Association. United Kingdom guidelines for living donor kidney transplantaton. 3rd Edition, 2011. http://www.bts.org.uk/Documents/Guidelines/Active/UK%20Guidelines%20 for%20Living%20Donor%20Kidney%20July%202011.pdf. Accessed November 12, 2015.
15. Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2006;8:417-426.
16. Cheng S, Fernandes VR, Bluemke DA, McClelland RL, Kronmal RA, Lima JA. Age-related left ventricular remodeling and associated risk for cardiovascular outcomes: the Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Imaging. 2009;2:191-198. doi: 10.1161/CIRCIMAGING.108.819938.
17. Taylor RJ, Moody WE, Umar F, Edwards NC, Taylor TJ, Stegemann B, Townend JN, Hor KN, Steeds RP, Mazur W, Leyva F. Myocardial strain measurement with feature-tracking cardiovascular magnetic resonance: normal values. Eur Heart J Cardiovasc Imaging. 2015;16:871-881. doi: 10.1093/ehjci/jev006.
18. Hudsmith LE, Cheng AS, Tyler DJ, Shirodaria C, Lee J, Petersen SE, Francis JM, Clarke K, Robson MD, Neubauer S. Assessment of left atrial volumes at 1.5 Tesla and 3 Tesla using FLASH and SSFP cine imaging. J Cardiovasc Magn Reson. 2007;9:673-679. doi: 10.1080/10976640601138805.
19. Chue CD, Edwards NC, Ferro CJ, Townend JN, Steeds RP. Effects of age and chronic kidney disease on regional aortic distensibility: a cardiovascular magnetic resonance study. Int J Cardiol. 2013;168:4249-4254. doi: 10.1016/j.ijcard.2012.08.007.
20. Groenink M, de Roos A, Mulder BJ, Spaan JA, van der Wall EE. Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. Am J Cardiol. 1998;82:203-208.
21. Jackson CE, Shirodaria CC, Lee JM, Francis JM, Choudhury RP, Channon KM, Noble JA, Neubauer S, Robson MD. Reproducibility and accuracy of automated measurement for dynamic arterial lumen area by cardiovascular magnetic resonance. Int J Cardiovasc Imaging. 2009;25:797-808. doi: 10.1007/s10554-009-9495-5.
22. Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intimamedia thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis. 2012;34:290-296. doi: 10.1159/000343145.
23. Mårtensson J, Groth S, Rehling M, Gref M. Chromium-51-EDTA clearance in adults with a single-plasma sample. J Nucl Med. 1998;39:2131-2137.
24. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
25. Gansevoort RT, Verhave JC, Hillege HL, Burgerhof JG, Bakker SJ, de Zeeuw D, de Jong PE. The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int Suppl. 2005:S28-S35.
26. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2012;3:S1-S150.
27. Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol. 2009;54:505-512. doi: 10.1016/j.jacc.2009.03.066.
28. Glassock R, Delanaye P, El Nahas M. An Age-Calibrated Classification of Chronic Kidney Disease. JAMA. 2015;314:559-560. doi: 10.1001/jama.2015.6731.
29. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038-2047. doi: 10.1001/jama.298.17.2038.
30. Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, Baicu CF, Massie BM, Carson PE; I-PRESERVE Investigators. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation. 2011;124:2491-2501. doi: 10.1161/CIRCULATIONAHA.110.011031.
31. Velagaleti RS, Gona P, Levy D, Aragam J, Larson MG, Tofler GH, Lieb W, Wang TJ, Benjamin EJ, Vasan RS. Relations of biomarkers representing distinct biological pathways to left ventricular geometry. Circulation. 2008;118:2252-2258, 5p following 2258. doi: 10.1161/CIRCULATIONAHA.108.817411.
32. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393-4408. doi: 10.1172/JCI46122.
33. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation. 2006;113:664-670. doi: 10.1161/CIRCULATIONAHA.105.579342.
34. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barré PE. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol. 1995;5:2024-2031.
35. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35:580-586.
36. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566. doi: 10.1056/NEJM199005313222203.
37. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA, McGuire DK. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304:2503-2512. doi: 10.1001/jama.2010.1768.
38. deFilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, Seliger SL. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010;304:2494-2502. doi: 10.1001/jama.2010.1708.
39. Scheven L, de Jong PE, Hillege HL, Lambers Heerspink HJ, van Pelt LJ, Kootstra JE, Bakker SJ, Gansevoort RT; PREVEND Study Group. High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. Eur Heart J. 2012;33:2272-2281. doi: 10.1093/eurheartj/ehs163.
40. Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham SA, Wareham NJ, Peters RJ, Jukema JW, Day NE, Kastelein JJ, Khaw KT. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis. 2006;187:415-422. doi: 10.1016/j.atherosclerosis.2005.09.023.
41. Vickery S, Webb MC, Price CP, John RI, Abbas NA, Lamb EJ. Prognostic value of cardiac biomarkers for death in a non-dialysis chronic kidney disease population. Nephrol Dial Transplant. 2008;23:3546-3553. doi: 10.1093/ndt/gfn341.
42. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 2000;102:470-479.
43. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305. doi: 10.1056/NEJMoa041031.
44. Organ Procurement and Transplantation Network. 2015. http://optn.transplant. hrsa.gov/converge/latestData/rptData.asp. Accessed July 14, 2015.
45. Fehrman-Ekholm I, Elinder CG, Stenbeck M, Tydén G, Groth CG. Kidney donors live longer. Transplantation. 1997;64:976-978.
46. Segev DL, Muzaale AD, Caffo BS, Mehta SH, Singer AL, Taranto SE, McBride MA, Montgomery RA. Perioperative mortality and long-term survival following live kidney donation. JAMA. 2010;303:959-966. doi: 10.1001/jama.2010.237.
47. Muzaale AD, Massie AB, Wang MC, Montgomery RA, McBride MA, Wainright JL, Segev DL. Risk of end-stage renal disease following live kidney donation. JAMA. 2014;311:579-586. doi: 10.1001/jama.2013.285141.
48. Mjøen G, Hallan S, Hartmann A, et al. Long-term risks for kidney donors. Kidney Int. 2014;86:162-167. doi: 10.1038/ki.2013.460.
49. Kasiske BL, Anderson-Haag T, Israni AK, Kalil RS, Kimmel PL, Kraus ES, Kumar R, Posselt AA, Pesavento TE, Rabb H, Steffes MW, Snyder JJ, Weir MR. A prospective controlled study of living kidney donors: three-year follow-up. Am J Kidney Dis. 2015;66:114-124. doi: 10.1053/j. ajkd.2015.01.019.
50. Kao MP, Ang DS, Gandy SJ, Nadir MA, Houston JG, Lang CC, Struthers AD. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol. 2011;22:1382-1389. doi: 10.1681/ASN.2010111185.
51. Laflamme MH, Mahjoub H, Mahmut A, Boulanger MC, Larose E, Pibarot P, Mathieu P. Parathyroid hormone is associated with the LV mass after aortic valve replacement. Heart. 2014;100:1859-1864. doi: 10.1136/hear tjnl-2014-305837.